ArticlePsychiatry investigation2019
Biological and Clinical Markers in Panic Disorder.
Article in Psychiatry investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Candidate Biological Markers for Social Anxiety Disorder: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- The lateral habenula regulates stress-related respiratory responses via the monoaminergic system.Pflugers Archiv : European journal of physiology · 2025Article
- Exploring Brainstem Structural Abnormalities: Potential Biomarkers for Panic Disorder.Experimental neurobiology · 2024Article
- Breaking the Fear Barrier: Aberrant Activity of Fear Networks as a Prognostic Biomarker in Patients with Panic Disorder Normalized by Pharmacotherapy.Biomedicines · 2023Article
- Depression and Anxiety Symptoms Are Associated with Mean Platelet Volume in Autoimmune Disorders.International journal of environmental research and public health · 2022Article
- Panic disorder in general medical practice- A narrative review.Journal of family medicine and primary care · 2022Review
- Biological Markers in Anxiety Disorders.Journal of clinical medicine · 2021Review
- Anticonvulsant and antipsychotic medications in the pharmacotherapy of panic disorder: a structured review.Therapeutic advances in psychopharmacology · 2021Review
- Panic disorder respiratory subtype: psychopathology and challenge tests - an update.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2020Article
- Panic Disorder: Current Research and Management Approaches.Psychiatry investigation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveClassifying mental disorders on the basis of objective makers might clarify their aetiology, help in making the diagnosis, identify "at risk" individuals, determine the severity of mental illness, and predict the course of the disorder. This study aims to review biological and clinical markers of panic disorder (PD).
methodsA computerized search was carried out in PubMed and Science Direct using the key words: "marker/biomarker/clinical marker/neurobiology/staging" combined using Boolean AND operator with "panic." In addition, the reference lists from existing reviews and from the articles retrieved were inspected. Only English language papers published in peer-reviewed journals were included.
resultsStructural changes in the amygdala, hippocampus, cerebral blood level in the left occipital cortex, serotonin 5-TH and noradrenergic systems activation, aberrant respiratory regulation, hearth rate variability, blood cells and peripheral blood stem cells, hypothalamic-pituitary-adrenal axis dysregulation were identified as potential candidate biomarkers of PD. Staging was identified as clinical marker of PD. According to the staging model, PD is described as follows: prodromal phase (stage 1); acute phase (stage 2); panic attacks (stage 3); chronic phase (stage 4).
conclusionThe clinical utility, sensitivity, specificity, and the predictive value of biomarkers for PD is still questionable. The staging model of PD might be a valid susceptibility, diagnostic, prognostic, and predictive marker of PD. A possible longitudinal model of biological and clinical markers of PD is proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.